Tilray Brands stock (NASDAQ: TLRY; TSX: TLRY) is back in the spotlight this Sunday, November 23, 2025, for all the reasons that make cannabis names both fascinating and stressful to follow:
the share price has slipped back under $1, new AI-driven trading plans dropped this morning, a fresh “millionaire maker” think-piece is circulating, and regulators are pulling the sector in opposite directions.
Here’s a full breakdown of everything new on Tilray today, plus the key numbers, fundamentals, and risks traders are weighing right now.
Tilray stock price snapshot for November 23, 2025
Because U.S. markets are closed today (Sunday), the latest tradable quote for Tilray is still Friday’s close:
- Last close (Nov 21, 2025):$0.9059
- After-hours (Nov 21): about $0.92 [1]
- Intraday range Friday: roughly $0.875–$0.95
- Volume: ~29.4 million shares, in line with Tilray’s heavy trading norms [2]
- Market cap: about $1.0–1.02 billion [3]
- 52‑week range:$0.35 – $2.32 [4]
- Beta (volatility vs market): ~2.1 – this is a high‑beta name. [5]
Price action recently has been rough:
- Over the past week (Nov 17–21), TLRY slid from about $1.03 to $0.91, a drop of roughly 12%, with five straight red days. [6]
- Zoom out six months, though, and the story changes: Tilray is still up around 90–110% from its late‑spring lows, fueled by optimism around U.S. cannabis rescheduling and a sector‑wide rally after Donald Trump publicly touted CBD’s potential benefits for seniors in late September. [7]
In other words, short‑term trend: down; medium‑term trend: still up sharply; long‑term trend: massively dilutive and volatile.
All the fresh Tilray stock news dated November 23, 2025
Today’s TLRY‑specific coverage clusters around three key pieces of content.
1. TechStock²: TLRY under $1, “tug‑of‑war” between AI signals and regulation
TechStock² (TechStock² / TS²) published a feature this morning titled:
“Tilray Brands (TLRY) on November 23, 2025: Stock Under $1, Fresh AI Trading Signals, and a Tug‑of‑War Between Fundamentals and Regulation.” TechStock²
Key takeaways from that piece:
- Price context: It highlights that TLRY is back under $1, with Friday’s close at $0.91, and notes this caps a bruising week that erased about 12% of the stock’s value. TechStock²+1
- Medium‑term performance: TS² points out that despite the week’s pain, Tilray has still roughly doubled over the last six months, backed by hopes for U.S. reform and speculative flows into cannabis names. TechStock²
- Regulatory push–pull: The article frames TLRY as being caught between:
- September’s Trump CBD endorsement, which sent Tilray up about 42% in a single day, and
- This month’s U.S. spending bill, which includes language that could effectively ban many hemp‑derived THC products, pressuring Canadian cannabis stocks again. [8]
The overall message: Tilray is trading like a penny stock whose fate is tightly tied to shifting U.S. cannabis and hemp policy and speculative sentiment.
2. Stock Traders Daily: new AI‑driven trading plan for TLRY
The most concrete trading signal published today comes from Stock Traders Daily, which posted a fresh “(TLRY) Advanced Equity Analysis” at 09:13 a.m. ET. [9]
Their AI‑assisted plan (for TLRY’s Canadian listing, but levels line up closely with the U.S. stock) includes:
- Long‑term trading plan:
- Buy zone: near $1.12
- Upside target: around $1.47
- Stop‑loss:$1.11 [10]
- Short setup:
- Short zone: near $1.47
- Downside target: around $1.12
- Stop‑loss:$1.48 [11]
- AI ratings for November 23:
- Near‑term: Weak
- Mid‑term: Weak
- Long‑term: Weak
- The note explicitly warns that “triggers may have already come,” implying that the “ideal” entry points might have passed and risk/reward is deteriorating. [12]
This is purely technical, trading‑plan material – not fundamental analysis. For news‑driven investors, the important takeaway is that one popular quant/trading shop now sees muted edge in TLRY at current levels, even as it sketches out tight long/short ranges for active traders.
3. Motley Fool / AOL: “Is Tilray Brands a Millionaire Maker?”
A separate article syndicated via AOL from The Motley Fool, titled “Is Tilray Brands a Millionaire Maker?”, also went live this morning. [13]
While we only see a short snippet, the framing tells you a lot:
- The piece explicitly raises the “millionaire maker” question — essentially asking whether buying TLRY at today’s beaten‑down price could realistically generate life‑changing returns.
- The snippet references Tilray’s average diluted share count, hinting that the article stresses how massive dilution and a ~1.1 billion‑share base limit per‑share upside, even if the business grows. [14]
Put together with the TS² and Stock Traders Daily coverage, today’s narrative around TLRY is less “rocket ship” and more “high‑beta, high‑dilution turnaround that might still be interesting if – and only if – the fundamentals keep improving.”
Very recent news setting the stage
Today’s coverage sits on top of a busy few days of Tilray headlines.
Shareholder meeting: governance reforms stall
TipRanks reported on November 22 about Tilray’s annual stockholders meeting held on November 18, 2025: [15]
- Shareholders re‑elected John Herhalt as a Class I director.
- They ratified PricewaterhouseCoopers as Tilray’s independent auditor.
- However, a proposal to declassify the board and change how directors can be removed failed, suggesting mixed support for governance changes among shareholders.
- TipRanks’ AI “Spark” tool currently rates TLRY as Neutral, citing ongoing losses, liquidity challenges, and bearish technicals despite progress on revenue and debt reduction. [16]
Bank of Montreal slashes its stake by 91.5%
On November 22, 2025, MarketBeat highlighted that Bank of Montreal Can had cut its Tilray position by 91.5% in Q2: [17]
- BMO sold 2,478,386 shares, leaving just 230,432 shares worth about $95,000.
- Tilray’s institutional ownership remains modest at around 9% of the float, underscoring that big money has not fully embraced the name. [18]
- MarketBeat notes that the Street’s consensus rating is “Hold” with a $2.00 average price target (two Buys, three Holds, two Sells). [19]
November 20: stock slides 6.5%
A separate MarketBeat alert from November 20 details how Tilray fell 6.5% in a single session, dropping to about $0.90 with roughly 41.5 million shares traded: [20]
- The note again stresses the mixed analyst picture:
- Jefferies: upgraded TLRY earlier this year and boosted its target to $2.00.
- ATB Cap Markets: cut the stock to “strong sell”.
- It also calls out Tilray’s low leverage (debt‑to‑equity ~0.15) and solid liquidity (quick ratio ~1.56; current ratio ~2.62), even as earnings remain negative. [21]
For traders, this recent stretch reads like a tug‑of‑war: improving balance sheet and some bullish analyst calls versus big institutional selling and heavy volatility.
Fundamentals: Tilray after its Q1 FY2026 “turnaround” quarter
The backbone of any Tilray thesis now is the Q1 fiscal 2026 report (quarter ended August 31, 2025), released on October 9.
Record revenue and first net profit in over a year
According to Tilray’s own release (via GlobeNewswire) and live coverage from 24/7 Wall St.: [22]
- Q1 FY2026 net revenue:$209.5 million,
- up about 5% year‑over‑year and
- above consensus estimates around $205.7 million.
- Segment revenue breakdown (approximate):
- Cannabis: $64.5M, +5% YoY
- Beverage (including craft beer): $55.7M, roughly flat YoY
- Wellness (e.g., Manitoba Harvest hemp foods): $15.2M, modest growth
- Distribution (CC Pharma and others): $74.0M, +9% YoY [23]
- Net income: about $1.5 million, versus a $34.7M loss a year earlier – Tilray’s first quarterly profit in over a year. [24]
- Adjusted EBITDA: around $10.2 million, up 9% YoY. [25]
- Adjusted EPS: roughly $0.00, in line with expectations. [26]
Management reaffirmed FY2026 adjusted EBITDA guidance of $62–72 million, signalling confidence that profitability and cash‑flow improvements are sustainable, not one‑off. [27]
But margins and growth still have issues
GuruFocus’ summary of the Q1 earnings call highlights both positives and pain points: [28]
Positives:
- Strengthening European footprint, including new permits in Portugal and extended reach through CC Pharma, which distributes to roughly 13,000 pharmacies in Germany.
- Ongoing cost reductions (about $25M in savings and several facility closures).
- A strong Canadian infrastructure base and readiness to pounce on U.S. rescheduling opportunities.
Negatives:
- Gross margins are still under pressure, especially in the beer and Canadian adult‑use segments.
- Germany’s quota system and regulatory frictions are slowing growth.
- Integrating multiple acquisitions across cannabis, beverage, wellness, and distribution remains complex and resource‑intensive. [29]
Full‑year 2025: revenue growth, massive accounting loss
StockAnalysis data shows Tilray posted in fiscal 2025: [30]
- Revenue: about $821.3 million, up 4.1% from $788.9 million in 2024.
- Net loss: roughly $2.19 billion, a huge increase versus the prior year, largely reflecting non‑cash charges, impairments, and restructuring costs layered onto an already unprofitable core business.
On a trailing basis:
- Revenue (TTM): ~$830.8 million
- Net income (TTM): around –$2.15 billion
- Shares outstanding: about 1.13 billion
- EPS (TTM): approximately –$2.30 per share [31]
These numbers explain why so many analysts and commentators stress that even if Tilray grows, the starting share count makes “millionaire maker” scenarios hard to pull off without truly extraordinary long‑term returns.
Strategy and messaging: Tilray leans into its “CPG powerhouse” story
On November 17, Tilray released an updated investor presentation and backed it up with a GlobeNewswire press release: [32]
Key themes from that update:
- Tilray wants to be viewed less as a pure “weed stock” and more as a diversified consumer packaged goods (CPG) platform operating at the intersection of beverages, cannabis, wellness, and entertainment.
- The presentation emphasises:
- Strategic vision: building one of the world’s most trusted lifestyle brands in these categories.
- Brand portfolio: more than 40 brands in over 20 countries, spanning craft beer, cannabis, hemp foods, and wellness.
- Operational excellence: continued focus on margin enhancement and disciplined capital allocation.
- Global expansion: growing positions across North America, Europe (especially Germany and Portugal), and other emerging markets. [33]
The messaging is clear: Tilray wants investors to think “beverage + cannabis + wellness CPG roll‑up” rather than just “Canadian LP fighting for share in a crowded domestic market.”
Hemp crackdown vs CBD optimism: regulatory crosscurrents
Regulation is front and center in today’s Tilray narrative.
Trump’s CBD endorsement: a big September boost
On September 29, cannabis stocks ripped higher after Donald Trump posted on Truth Social about CBD’s potential to “revolutionize senior healthcare.” Reuters reported that: [34]
- Tilray’s U.S. shares jumped about 42% in a single session,
- while other cannabis names and marijuana‑focused ETFs gained 15–30%+, as traders bet on eventual rescheduling and tax relief.
That rally drove much of the six‑month performance that today’s articles reference.
November spending bill: backlash against hemp‑derived THC
Fast‑forward to this month and the mood has darkened. A U.S. government spending bill included language that would severely restrict many hemp‑derived THC products, prompting a selloff in Canadian cannabis names and alarm among hemp beverage makers. [35]
In direct response, Tilray issued a strongly worded November 11 press release: [36]
- It condemned the hemp language as “misguided” and “out of touch with consumer interests.”
- Tilray argued that prohibition would push consumers toward unregulated, unsafe products, hurting responsible operators.
- The company backs a federal baseline framework allowing hemp‑derived THC beverages up to 10mg of delta‑9 THC per serving, paired with state‑level flexibility.
- Importantly, Tilray noted that hemp‑derived THC beverages are not yet a material piece of its revenue or EBITDA, but sees the category as a billion‑dollar U.S. market that deserves rational regulation. [37]
This backdrop explains why today’s TS² and analytic coverage keeps returning to a “tug‑of‑war” between regulatory tailwinds (rescheduling, CBD rhetoric) and headwinds (hemp rules in the spending bill).
Balance sheet, debt swaps and reverse‑split overhang
Even with net profits just beginning to appear, Tilray has spent years reshaping its capital structure.
Debt-for-equity and restructuring
An 8‑K summary tracked by StockInsights notes that on June 16, 2025, Tilray: [38]
- Exchanged 12,591,816 shares of common stock for $5 million in convertible senior notes.
- This was one of several debt‑for‑equity transactions completed over 2024–2025, part of a broader effort to pare down debt and improve leverage.
Separately, Cannabis Business Times reported that in the quarter ended February 28, 2025, Tilray: [39]
- Reduced total debt by about $76 million,
- Bringing net debt to less than 1.0x trailing twelve‑month adjusted EBITDA, and
- Gained shareholder approval for a potential reverse stock split — though the company has paused implementation, watching the share price and market conditions.
These moves have helped produce the low debt‑to‑equity ratio (~0.15) and comfortably positive liquidity metrics highlighted in recent MarketBeat pieces. [40]
The flip side, of course, is that all this restructuring has swollen the share count, putting ongoing pressure on per‑share metrics and making future upside more dependent on real operating growth rather than just sentiment.
Analyst sentiment and signals: “Hold” on fundamentals, “weak” on technicals
Different analyst platforms paint a subtly different picture, but the tone is broadly cautious:
- MarketBeat:
- StockAnalysis:
- Aggregates three analyst ratings and labels the consensus “Buy”,
- With a $1.50 price target implying about 65% upside from the latest price. [43]
- TipRanks:
- Cites the “most recent” analyst rating as a Hold with a $1.00 target, and
- Its AI “Spark” model assigns TLRY a Neutral score, flagging weak financial performance and bearish technical momentum. [44]
- Haywood / Cantech Letter (earlier in October):
- Maintained a Hold but raised their target after Q1 FY2026 results came in slightly ahead of expectations. [45]
Layered on top of this, the Stock Traders Daily AI trading plan published today rates TLRY as “Weak” across near, mid, and long horizons, with both long and short setups that rely on tight stops — a sign that even trading models see TLRY as a high‑risk, tactical instrument rather than a stable trend play right now. [46]
Key risks and opportunities for Tilray stock at today’s levels
Nothing here is personalized investment advice, but based on today’s news and recent filings, the risk‑reward profile looks something like this.
Potential upside drivers
- Balance sheet much cleaner
Net debt has been sharply reduced through debt‑for‑equity swaps and cash generation, leaving leverage low and giving Tilray more breathing room than many cannabis peers. [47] - First steps toward sustainable profitability
Q1 FY2026 delivered record revenue, positive net income, and higher EBITDA, while FY2026 guidance continues to call for meaningful profitability improvements. [48] - Diversification beyond flower
The investor presentation and recent press releases underscore that Tilray now spans craft beer, hemp foods, wellness, and medical cannabis, reducing reliance on any single category or region. [49] - Regulatory optionality
U.S. rescheduling of cannabis and rational hemp regulations could unlock tax relief, new markets, and institutional access — factors that helped ignite September’s big sector rally. [50]
Major risks
- Extreme dilution and low share price
With ~1.13 billion shares outstanding and a sub‑$1 quote, TLRY behaves like a penny stock with big‑cap‑style news flow. Reverse‑split risk and further equity raises remain on the table. [51] - Profitability still fragile
One profitable quarter doesn’t erase years of losses or structural margin pressures in cannabis, beer, and distribution. GuruFocus and others note that gross margins and certain segments are still underperforming. [52] - Regulatory whiplash
The same U.S. political environment that gave Tilray a 42% pop on CBD optimism can also deliver hemp‑product crackdowns that hurt volumes and sentiment overnight. [53] - Institutional skepticism
BMO’s 91.5% position cut, relatively low institutional ownership, and mixed analyst ratings all suggest that large, conservative investors remain wary. [54] - High volatility
A beta over 2.0, heavy retail interest, and frequent double‑digit daily moves mean that TLRY can move violently on headlines — in both directions. [55]
What today’s news means for TLRY traders and long-term investors
Putting it all together, November 23, 2025 looks like an inflection‑point kind of day for Tilray coverage:
- Short‑term traders are being served fresh AI‑driven trading plans and tight technical levels from Stock Traders Daily, alongside reminders from MarketBeat about recent 6.5% down days and heavy volume. [56]
- Medium‑term speculators are digesting the idea that Tilray is:
- Profitable (barely),
- Significantly de‑levered, and
- Still highly exposed to U.S. policy shifts and sentiment surges, as seen in September. [57]
- Long‑term investors are being reminded, especially by today’s Motley Fool “millionaire maker” debate, that share count and dilution matter as much as top‑line growth when you think in decade‑long horizons. [58]
If you’re considering TLRY after today’s news, the key questions to ask yourself are:
- Am I investing in a multi‑year CPG turnaround, or am I trading sector headlines and technicals?
- Do I understand how much growth it would actually take for per‑share value to multiply from a base of ~1.1 billion shares?
- Can I emotionally and financially handle a stock that can move 10–20% in a day on a single tweet, bill draft, or analyst note?
For now, Tilray remains a high‑beta, high‑dilution cannabis/CPG hybrid:
one that is finally showing signs of financial progress, but still lives at the mercy of politics, regulation, and trader psychology.
References
1. stockanalysis.com, 2. stockanalysis.com, 3. stockanalysis.com, 4. stockanalysis.com, 5. stockanalysis.com, 6. stockanalysis.com, 7. www.reuters.com, 8. www.reuters.com, 9. news.stocktradersdaily.com, 10. news.stocktradersdaily.com, 11. news.stocktradersdaily.com, 12. news.stocktradersdaily.com, 13. www.aol.com, 14. www.aol.com, 15. www.tipranks.com, 16. www.tipranks.com, 17. www.marketbeat.com, 18. www.marketbeat.com, 19. www.marketbeat.com, 20. www.marketbeat.com, 21. www.marketbeat.com, 22. 247wallst.com, 23. 247wallst.com, 24. 247wallst.com, 25. 247wallst.com, 26. 247wallst.com, 27. 247wallst.com, 28. www.gurufocus.com, 29. www.gurufocus.com, 30. stockanalysis.com, 31. stockanalysis.com, 32. www.globenewswire.com, 33. www.globenewswire.com, 34. www.reuters.com, 35. seekingalpha.com, 36. www.globenewswire.com, 37. www.globenewswire.com, 38. www.stockinsights.ai, 39. www.cannabisbusinesstimes.com, 40. www.marketbeat.com, 41. www.marketbeat.com, 42. www.marketbeat.com, 43. stockanalysis.com, 44. www.tipranks.com, 45. www.cantechletter.com, 46. news.stocktradersdaily.com, 47. 247wallst.com, 48. 247wallst.com, 49. www.globenewswire.com, 50. www.reuters.com, 51. stockanalysis.com, 52. www.gurufocus.com, 53. www.reuters.com, 54. www.marketbeat.com, 55. stockanalysis.com, 56. news.stocktradersdaily.com, 57. 247wallst.com, 58. www.aol.com
